Exelixis | EXEL - Operating Expenses

Stock Price
43.08
Daily Change
0.27 0.63%
Monthly
1.60%
Yearly
30.07%
Q1 Forecast
40.09

Exelixis reported $341.4M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Bayer EUR 10.2B 523M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Eisai JPY 183.69B 1.78B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Exelixis USD 341.4M 13.29M Sep/2025
Genmab DKK 565M 38M Jun/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Xencor USD 68.52M 8.26M Sep/2025